Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline

Feng Han, Gregory L Brown, Yalin Zhu, Aaron E Belkin-Rosen, Mechelle M Lewis, Guangwei Du, Yameng Gu, Paul J Eslinger, Richard B Mailman, Xuemei Huang, Xiao Liu, Feng Han, Gregory L Brown, Yalin Zhu, Aaron E Belkin-Rosen, Mechelle M Lewis, Guangwei Du, Yameng Gu, Paul J Eslinger, Richard B Mailman, Xuemei Huang, Xiao Liu

Abstract

Background: Deposition and spreading of misfolded proteins (α-synuclein and tau) have been linked to Parkinson's disease cognitive dysfunction. The glymphatic system may play an important role in the clearance of these toxic proteins via cerebrospinal fluid (CSF) flow through perivascular and interstitial spaces. Recent studies discovered that sleep-dependent global brain activity is coupled to CSF flow, which may reflect glymphatic function.

Objective: The objective of this current study was to determine if the decoupling of brain activity-CSF flow is linked to Parkinson's disease cognitive dysfunction.

Methods: Functional and structural MRI data, clinical motor (Unified Parkinson's Disease Rating Scale), and cognitive (Montreal Cognitive Assessment [MoCA]) scores were collected from 60 Parkinson's disease and 58 control subjects. Parkinson's disease patients were subgrouped into those with mild cognitive impairment (MoCA < 26), n = 31, and those without mild cognitive impairment (MoCA ≥ 26), n = 29. The coupling strength between the resting-state global blood-oxygen-level-dependent signal and associated CSF flow was quantified, compared among groups, and associated with clinical and structural measurements.

Results: Global blood-oxygen-level-dependent signal-CSF coupling decreased significantly (P < 0.006) in Parkinson's disease patients showing mild cognitive impairment, compared with those without mild cognitive impairment and controls. Reduced global blood-oxygen-level-dependent signal-CSF coupling was associated with decreased MoCA scores present in Parkinson's disease patients (P = 0.005) but not in controls (P = 0.65). Weaker global blood-oxygen-level-dependent signal-CSF coupling in Parkinson's disease patients also was associated with a thinner right entorhinal cortex (Spearman's correlation, -0.36; P = 0.012), an early structural change often seen in Alzheimer's disease.

Conclusions: The decoupling between global brain activity and associated CSF flow is related to Parkinson's disease cognitive impairment. © 2021 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; cerebrospinal fluid flow; cognitive impairment; global resting-state fMRI signal; glymphatic system.

© 2021 International Parkinson and Movement Disorder Society.

Figures

Fig. 1.. Systematic coupling between the gBOLD…
Fig. 1.. Systematic coupling between the gBOLD and CSF signals measured by rsfMRI.
(A) The gBOLD and CSF fMRI signals were extracted from the whole-brain gray matter regions (the blue mask on a T1-weighted structural MRI in the left panel) and the CSF region at the bottom slice of the fMRI acquisition (the bright region in the right panel and the orange-shaded area in the middle panel), respectively. (B) The gBOLD and CSF signal from a representative subject (control) showed corresponding changes of large amplitude. Large CSF peaks (upwards black arrows) often are preceded by a large positive gBOLD peak (downwards black arrows) and followed by a large negative gBOLD peak (gray arrows). (C) The averaged cross-correlation function (N =118 subjects) between the gBOLD signal (reference) and the CSF signal (left), as well as between the first-order negative derivative of gBOLD signal (reference) and the CSF signal (right). The gray dashed line and the shaded region mark 95% confidence intervals for the mean correlation computed on shuffled signals (see Materials and methods for details). The cross-correlations between the gBOLD and CSF signal at the +4 seconds lag (mean r: −0.28; p < 0.0001, permutation test with N =10,000; red dashed line) was used to represent “the gBOLD-CSF coupling” for subsequent analyses.
Fig. 2.. The associations of gBOLD-CSF coupling…
Fig. 2.. The associations of gBOLD-CSF coupling to age, disease condition, and MoCA.
(A) Older subjects have a weaker (less negative) gBOLD-CSF coupling (Spearman’s ρ = 0.32, p = 0.0005). (B) Compared with controls and PD-non-MCI subjects, PD-MCI subjects have decreased gBOLD-CSF coupling strength (adjusted for age and gender; p ≤ 0.006, two-sample t-test). (C-D) The correlation between the gBOLD-CSF coupling (adjusted for age and gender) and MoCA scores is significant in the PD group (ρ = −0.36, p = 0.005, pBonferroni = 0.01; D) but not in the controls (ρ = −0.06, p = 0.65; C). (E) The significant correlation between gBOLD-CSF coupling and MoCA within PD subjects remained significant when removing the two subjects with extremely low MoCA scores (ρ = −0.31, p = 0.017, pBonferroni = 0.034). The dashed lines indicate where the gBOLD-CSF coupling equals zero.
Fig. 3.. Associations between gBOLD-CSF coupling and…
Fig. 3.. Associations between gBOLD-CSF coupling and thickness of the entorhinal cortex in PD patients.
The PD patients with thinner right ERC tend to have weaker gBOLD-CSF coupling (Spearman’s ρ = −0.36, p = 0.012, pBonferroni = 0.024) (A). This association is similar but not significant (ρ = −0.19, p = 0.19, pBonferroni = 0.38) for the left ERC (B). The ERC thickness was normalized with the Sienax index.

References

    1. Parkinson J. An essay on shaking palsy. 1817; 14: 223–236.
    1. Venda LL, Cragg SJ, Buchman VL, Wade-Martins R. α-Synuclein and dopamine at the crossroads of Parkinson’s disease. Trends Neurosci. 2010; 33: 559–568.
    1. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci 2010; 289: 18–22.
    1. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol. 2000; 100: 285–290.
    1. Hurtig HI, Trojanowski JQ, Galvin J, et al.Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology. 2000; 54: 1916–1921.
    1. Lei P, Ayton S, Finkelstein DI, et al.Tau protein: Relevance to Parkinson’s disease. Int. J. Biochem. Cell Biol 2010; 42: 1775–1778.
    1. Zhang X, Gao F, Wang D, et al.Tau pathology in Parkinson’s disease. Front. Neurol 2018; 9.
    1. Goris A, Williams-Gray CH, Clark GR, et al.Tau and α-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann. Neurol 2007; 62: 145–153.
    1. Vermersch P, Delacourte A, Javoy‐Agid F, Hauw J‐J, Agid Y. Dementia in Parkinson’s disease: Biochemical evidence for cortical involvement using the immunodetection of abnormal tau proteins. Ann. Neurol 1993; 33: 445–450.
    1. Irwin DJ, Grossman M, Weintraub D, et al.Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017; 16: 55–65.
    1. Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. The Glymphatic System: A Beginner’s Guide. Neurochem. Res 2015; 40: 2583–2599.
    1. Sundaram S, Hughes RL, Peterson E, et al.Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson’s disease. Neurosci. Biobehav. Rev 2019; 103: 305–315.
    1. Valdinocci D, Radford RAW, Goulding M, et al.Extracellular interactions of Alpha-synuclein in multiple system atrophy. Int. J. Mol. Sci 2018; 19: 4219.
    1. Tarasoff-Conway JM, Carare RO, Osorio RS, et al.Clearance systems in the brain - Implications for Alzheimer disease. Nat. Rev. Neurol 2015; 11: 457–470.
    1. Holth JK, Fritschi SK, Wang C, et al.The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science (80-. ) 2019; 363: 880–884.
    1. Mestre H, Mori Y, Nedergaard M. The Brain’s Glymphatic System: Current Controversies. Trends Neurosci. 2020; 43: 458–466.
    1. Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp. Mol. Med 2015; 47: e148.
    1. Xie L, Kang H, Xu Q, et al.Sleep drives metabolite clearance from the adult brain. Science (80-. ) 2013; 342: 373–377.
    1. Iliff JJ, Wang M, Liao Y, et al.A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med 2012; 4: 147.
    1. Iliff JJ, Lee H, Yu M, et al.Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J. Clin. Invest 2013; 123: 1299–1309.
    1. Eide PK, Ringstad G. MRI with intrathecal MRI gadolinium contrast medium administration: a possible method to assess glymphatic function in human brain. Acta Radiol. Open 2015; 4: 1–5.
    1. Ringstad G, Valnes LM, Dale AM, et al.Brain-wide glymphatic enhancement and clearance in humans assessed with MRI. JCI insight. 2018; 3: e121537.
    1. Taoka T, Masutani Y, Kawai H, et al.Evaluation of glymphatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer’s disease cases. Jpn. J. Radiol 2017; 35: 172–178.
    1. Harrison IF, Siow B, Akilo AB, et al.Non-1 invasive imaging of CSF-mediated brain clearance pathways via assessment of perivascular fluid movement with diffusion tensor MRI. Elife. 2018; 7: e34028.
    1. Kiviniemi V, Wang X, Korhonen V, et al.Ultra-fast magnetic resonance encephalography of physiological brain activity-Glymphatic pulsation mechanisms? J. Cereb. Blood Flow Metab 2016; 36: 1033–1045.
    1. Fukunaga M, Horovitz SG, van Gelderen P, et al.Large-amplitude, spatially correlated fluctuations in BOLD fMRI signals during extended rest and early sleep stages. Magn. Reson. Imaging 2006; 24: 979–972.
    1. Horovitz SG, Fukunaga M, De Zwart JA, et al.Low frequency BOLD fluctuations during resting wakefulness and light sleep: A simultaneous EEG-fMRI study. Hum. Brain Mapp 2008; 29: 671–682.
    1. Liu X, De Zwart JA, Schölvinck ML, et al.Subcortical evidence for a contribution of arousal to fMRI studies of brain activity. Nat. Commun 2018; 9: 395.
    1. Özbay PS, Chang C, Picchioni D, et al.Contribution of systemic vascular effects to fMRI activity in white matter. Neuroimage. 2018; 176: 541–549.
    1. Shmueli K, van Gelderen P, de Zwart JA, et al.Low-frequency fluctuations in the cardiac rate as a source of variance in the resting-state fMRI BOLD signal. Neuroimage. 2007; 38: 306–320.
    1. Chang C, Cunningham JP, Glover GH. Influence of heart rate on the BOLD signal: The cardiac response function. Neuroimage. 2009; 44: 857–869.
    1. Birn RM, Diamond JB, Smith MA, Bandettini PA. Separating respiratory-variation-related fluctuations from neuronal-activity-related fluctuations in fMRI. Neuroimage. 2006; 31: 1536–1548.
    1. Power JD, Plitt M, Gotts SJ, et al.Ridding fMRI data of motion-related influences: Removal of signals with distinct spatial and physical bases in multiecho data. Proc. Natl. Acad. Sci. U. S. A 2018; 115: E2105–E2114.
    1. Gu Y, Han F, Sainburg LE, Liu X. Transient Arousal Modulations Contribute to Resting-State Functional Connectivity Changes Associated with Head Motion Parameters. Cereb. Cortex 2020; 30: 5242–5256.
    1. Tong Y, Yao J (Fiona), Chen JJ, Frederick B de B. The resting-state fMRI arterial signal predicts differential blood transit time through the brain. J. Cereb. Blood Flow Metab 2019; 39: 1148–1160.
    1. Schley D, Carare-Nnadi R, Please CP, Perry VH, Weller RO. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J. Theor. Biol 2006; 238: 962–974.
    1. Iliff JJ, Wang M, Zeppenfeld DM, et al.Cerebral arterial pulsation drives paravascular CSF-Interstitial fluid exchange in the murine brain. J. Neurosci 2013; 33: 18190–18199.
    1. Klose U, Strik C, Kiefer C, Grodd W. Detection of a relation between respiration and CSF pulsation with an echoplanar technique. J. Magn. Reson. Imaging 2000; 11: 438–444.
    1. Yamada S, Miyazaki M, Yamashita Y, et al.Influence of respiration on cerebrospinal fluid movement using magnetic resonance spin labeling. Fluids Barriers CNS. 2013; 10: 36.
    1. Mestre H, Tithof J, Du T, et al.Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat. Commun 2018; 9: 4878.
    1. Fultz NE, Bonmassar G, Setsompop K, et al.Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science (80-. ) 2019; 366: 628–631.
    1. Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med 2012; 2: a009399.
    1. Emmanouilidou E, Elenis D, Papasilekas T, et al.Assessment of α-synuclein secretion in mouse and human brain parenchyma. PLoS One. 2011; 6: e22225.
    1. Harrison IF, Ismail O, Machhada A, et al.Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model. Brain. 2020; 143: 2576–2 593.
    1. Wills J, Jones J, Haggerty T, et al.Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp. Neurol 2010; 225: 210–218.
    1. Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson’s disease dementia: Convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci 2013; 14: 626–636.
    1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992; 55: 181–184.
    1. Goetz CG, Fahn S, Martinez-Martin P, et al.Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov. Disord 2007; 22: 41–47.
    1. Lewis MM, Harkins E, Lee EY, et al.Clinical Progression of Parkinson’s Disease: Insights from the NINDS Common Data Elements. J. Parkinsons. Dis 2020; 10: 1075–1085.
    1. Tomlinson CL, Stowe R, Patel S, et al.Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord 2010; 25: 2649–2653.
    1. Nasreddine ZS, Phillips NA, Bédirian V, et al.The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc 2005; 53: 695–699.
    1. Hoops S, Nazem S, Siderowf AD et al.Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009; 73: 1738–1745.
    1. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al.The MoCA: Well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010; 75: 1717–1725.
    1. Biswal BB, Mennes M, Zuo XN, et al.Toward discovery science of human brain function. Proc. Natl. Acad. Sci. U. S. A 2010; 107: 4734–4739.
    1. Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J. A probabilistic atlas of the human brain: Theory and rationale for its development. Neuroimage. 1995; 2: 89–101.
    1. Babiloni C, Frisoni GB, Pievani M, et al.Hippocampal volume and cortical sources of EEG alpha rhythms in mild cognitive impairment and Alzheimer disease. Neuroimage. 2009; 44: 123–135.
    1. Velayudhan L, Proitsi P, Westman E, et al.Entorhinal cortex thickness predicts cognitive decline in Alzheimer’s disease. J. Alzheimer’s Dis 2013; 33: 755–766.
    1. Fjell AM, Westlye LT, Grydeland H, et al.Accelerating cortical thinning: Unique to dementia or universal in aging? Cereb. Cortex 2014; 24: 919–934.
    1. Ma X, Li Z, Jing B, et al.Identify the atrophy of Alzheimer’s disease, mild cognitive impairment and normal aging using morphometric MRI analysis. Front. Aging Neurosci 2016; 8: 243.
    1. Fischl B. FreeSurfer. Neuroimage. 2012; 62: 774–781.
    1. Hoops S, Nazem S, Siderowf AD, et al.Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009; 75: 478.
    1. Smith SM, Zhang Y, Jenkinson M, et al.Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002; 17: 479–489.
    1. Aquino KM, Fulcher BD, Parkes L, Sabaroedin K, Fornito A. Identifying and removing widespread signal deflections from fMRI data: Rethinking the global signal regression problem. Neuroimage. 2020; 212: 116614.
    1. Desikan RS, Ségonne F, Fischl B, et automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006; 31: 968–980.
    1. Gao JH, Liu HL. Inflow effects on functional MRI. Neuroimage. 2012; 62: 1035–1039.
    1. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage. 2012; 59: 2142–2154.
    1. Chang C, Leopold DA, Schölvinck ML, et al.Tracking brain arousal fluctuations with fMRI. Proc. Natl. Acad. Sci. U. S. A 2016; 113: 4518–4523.
    1. Fisher RA. On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P. J. R. Stat. Soc 1922; 85: 87–94.
    1. Bonferroni CE. 1936Teoria statistica delle classi e calcolo delle probabilità. Pubbl. del R Ist. Super. di Sci. Econ. e Commer. di Firenze 19366; 1493–1494.
    1. Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: Regional thinning predicts mild AD dementia. Neurology. 2009; 72:1048–1055.
    1. Yeo BTT, Tandi J, Chee MWL. Functional connectivity during rested wakefulness predicts vulnerability to sleep deprivation. Neuroimage. 2015; 111: 147–158.
    1. Wong CW, Olafsson V, Tal O, Liu TT. The amplitude of the resting-state fMRI global signal is related to EEG vigilance measures. Neuroimage. 2013; 83: 983–990.
    1. Kiviniemi VJ, Haanpää H, Kantola JH, et al.Midazolam sedation increases fluctuation and synchrony of the resting brain BOLD signal. Magn. Reson. Imaging 2005; 23: 531–537.
    1. van Veluw SJ, Hou SS, Calvo-Rodriguez M, et al.Vasomotion as a Driving Force for Paravascular Clearance in the Awake Mouse Brain. Neuron. 2020; 105: 549–561.
    1. Thompson PM, Hayashi KM, De Zubicaray G, et al.Dynamics of gray matter loss in Alzheimer’s disease. J. Neurosci 2003; 23: 994–1005.
    1. Long X, Zhang L, Liao W, Jiang C, Qiu B. Distinct laterality alterations distinguish mild cognitive impairment and Alzheimer’s disease from healthy aging: Statistical parametric mapping with high resolution MRI. Hum. Brain Mapp 2013; 34: 3400–3410.
    1. Braak H, Braak E. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci. Res 1992; 15: 6–31.
    1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239–259.
    1. Braak H, Del Tredici K, Rüb U, et al.Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 2003; 24: 197–211.
    1. Chou KL, Lenhart A, Koeppe RA et al.Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: Cognitive and neurochemical correlates. Park Relat Disord. 2014; 20:1076–1080.
    1. Helakari H, Korhonen V, Holst SC et al.Sleep-specific changes in physiological brain pulsations. bioRxiv. 2020.
    1. Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis. Neurobiol. Dis 2012; 46: 572–590.
    1. Postuma RB, Montplaisir J, Lanfranchi P et al.Cardiac autonomic denervation in Parkinson’s disease is linked to REM sleep behavior disorder. Mov Disord. 2011; 26: 1529–1533.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe